MDGL
Madrigal Pharmaceuticals, Inc.
$211.12
Earnings Summary
Revenue | $14.64Mn |
Net Profits | $-151.97Mn |
Net Profit Margins | -1038.2% |
Highlights
Madrigal Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $14.64Mn in the Q2 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated +Inf% jump in its revenue since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit fell -77.12% since last year same period to $-151.97Mn in the Q2 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -3% fall in its net profits since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -1038.2% in the Q2 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Madrigal Pharmaceuticals, Inc. post its latest quarter earnings
EPS Estimate Current Year | -6.28 |
Highlights
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -6.28.
Key Ratios
Key ratios of the Madrigal Pharmaceuticals, Inc. post its Q2 2024 earnings
Earning Per Share (EPS) | -7.1 |
Highlights
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) fell -51.39% since last year same period to -7.1 in the Q2 2024. This indicates that the Madrigal Pharmaceuticals, Inc. has generated -51.39% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-08-07 | -7.53 | -7.1 | 5.71% |
2024-05-07 | -6.28 | -7.38 | -17.52% |
₹0 US Stocks a/c Opening Fee